Skip to content
Back to meeting Original
Jia (Jenny) Liu MD PhD· @JiaJennyLiu · X·· 17 hours agoScore70
Body

Exciting!

Great to have participated in the phase 1 trial G042144 of divarasib led by @RashaCosman from #SVHA and see its phase 3 success at #ESMO26

8 views · 0 likes · 0 reposts · 0 replies

引用@
New standard of care for KRAS G12C mutation positive NSCLC. @FSkoulidis presents Krascendo-1 head to head trial of divarasib vs sotorasib or adagrasib- convincing improving PFS (9.8 m vs 5.7 m, HR 0.58) and OS (17.7m vs 12.0m, HR 0.58)
在 X 查看被引用的帖子

Source: Jia (Jenny) Liu MD PhD · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.